Graf Akcie ADAP (Adaptimmune Therapeutics Plc). Diskuze k akciím ADAP. Aktuální informace ADAP.

Základní informace o společnosti Adaptimmune Therapeutics Plc (Akcie ADAP)

Skvělé pro velmi rychlou analýzu společnosti. Investor může porovnat různé ukazatele s konkurenčními firmami.

Tržní kapitalizace 808.54M
Hodnota podniku (EV) N/A
Tržby 6.224M
EBITDA N/A
Zisk -148.88
Růst v tržbách Q/Q 516.53 %
Růst v tržbách Y/Y 179.35 %
P/E (Cena vůči ziskům) 0.00
Forward P/E N/A
EV/Sales 87.69
EV/EBITDA N/A
EV/EBIT N/A
PEG N/A
Price/Sales 129.91
P/FCF N/A
Price/Book 2.37
Účetní hodnota na akcii 2.25
Hotovost na akcii 2.45
FCF vůči ceně -15.87 %
Počet zaměstnanců 2,020
Tržba na zaměstnance 3.081k
Profit margin -3,286.81 %
Operating margin -2,419.49 %
Gross margin 100.00 %
EBIT margin -2,384.88 %
EBITDA margin -4,599.77 %
EPS - Zisk na akcii N/A
EPS - Kvartální růst 0.00 %
EPS - Očekávaný růst příští rok 8.33 %
Return on assets -34.39 %
Return on equity -45.65 %
ROIC -41.07 %
ROCE -42.61 %
Dluhy/Equity 0.32
Čistý dluh/EBITDA 7.00
Current ratio 8.15
Quick Ratio 8.15
Volatilita 5.83
Beta 1.38
RSI 51.41
Cílová cena analytiků 11
Známka akcie (dle analytiků) N/A
Insider ownership 0.12 %
Institutional ownership 77.31 %
Počet akcií 156.088M
Procento shortovaných akcií 0.00 %
Short ratio 0.83 %
Dividenda N/A
Procentuální dividenda N/A %
Dividenda/Zisk N/A %
Obchodovaná od 2015
Země United Kingdom

Finanční výsledky akcie ADAP

Finanční výsledky společnosti, napoví investorovi, zda se jedná o kvalitní společnost.

# 2020 2019 2018 2017 2016 2015
Revenue$1.122$59.505$37.833$14.198$10.746$0.577$0.577
Cost Of Goods Sold-------
Gross Profit$1.122$59.505$37.833$14.198$10.746$0.577$0.577
Research And Development Expenses$97.501$98.269$87.388$63.789$23.246$11.965$11.96
SG&A Expenses$43.391$43.601$31.106$23.208$11.35$2.606$2.337
Other Operating Income Or Expenses----$0.728$0.268-
Operating Expenses$140.892$141.87$118.494$86.997$33.867$14.302$14.297
Operating Income$-139.77$-82.365$-80.661$-72.799$-23.121$-13.724$-13.72
Total Non-Operating Income/Expense$2.847$-12.652$10.974$2.112$-0.627$-0.003$-0.003
Pre-Tax Income$-136.923$-95.017$-69.687$-70.687$-23.749$-13.728$-13.728
Income Taxes$0.242$0.497$0.451$0.892$-2.11$-1.597$-1.597
Income After Taxes$-137.165$-95.514$-70.138$-71.579$-21.638$-12.13$-12.131
Other Income-------
Income From Continuous Operations$-137.165$-95.514$-70.138$-71.579$-21.638$-12.13$-12.131
Income From Discontinued Operations-------
Net Income$-137.165$-95.514$-70.138$-71.579$-21.638$-12.13$-12.13
EBITDA$-131.76$-74.555$-75.238$-69.513$-22.387$-13.485$-13.72
EBIT$-139.77$-82.365$-80.661$-72.799$-23.121$-13.724$-13.72
Basic Shares Outstanding105978871540-
Shares Outstanding105978871540-
Basic EPS$-1.32$-0.96$-0.78$-1.02$-0.38$-48.80-
EPS - Earnings Per Share$-1.32$-0.96$-0.78$-1.02$-0.38$-48.80-
# 2020 2019 2018 2017 2016 2015
Current Ratio3.50869.45683.09744.935511.02831.0184
Long-term Debt / Capital------
Debt/Equity Ratio------
Gross Margin100100100100100100
Operating Margin-12457.22-138.4169-213.2028-512.7413-215.1657-2376.901
EBIT Margin-12457.22-138.4169-213.2028-512.7413-215.1657-2376.901
EBITDA Margin-11743.32-125.292-198.8687-489.5971-208.3309-2335.493
Pre-Tax Profit Margin-12203.48-159.679-184.1963-497.8659-221.0032-2377.465
Net Profit Margin-12225.04-160.5142-185.3884-504.1485-201.364-2100.845
Asset Turnover0.00620.2150.13460.06050.03570.0109
Inventory Turnover Ratio------
Receiveable Turnover-309.9219183.65539.59321.00660.2149
Days Sales In Receivables-1.17771.987438.0476362.59091698.535
ROE - Return On Equity-110.9408-38.6876-34.5535-43.083-8.3159-527.067
Return On Tangible Equity-112.9488-38.9199-34.7826-43.4144-8.3216-527.067
ROA - Return On Assets-75.5551-34.5145-24.9471-30.5221-7.1801-22.8794
ROI - Return On Investment-110.9408-38.6877-34.5535-43.083-8.3159-527.0671
Book Value Per Share1.17562.36082.16662.34663.6767.6137
Operating Cash Flow Per Share0.0001-0.45420.0628-0.0748-144.2634143.6577
Free Cash Flow Per Share0.025-0.2204-0.0486-0.1489-138.7593138.0652